Immunological Complications and Treatment of Cryptorchidism in Children: A Surgical and Immunotherapeutic Perspective-Scilight

Trends in Immunotherapy

Article

Immunological Complications and Treatment of Cryptorchidism in Children: A Surgical and Immunotherapeutic Perspective

Downloads

https://doi.org/10.54963/ti.v9i2.1207
Azis Elgondiev, Mustofa Aidid, Talant Omurbekov, Bolotbek Esembaev, Vladimir Poroshchai, Bakit Duysheubaev Oruzbaev, Chyngyz Temirkulov, Safiyat Emiraslanova, & Yethindra Vityala. (2025). Immunological Complications and Treatment of Cryptorchidism in Children: A Surgical and Immunotherapeutic Perspective. Trends in Immunotherapy, 9(2), 118–128. https://doi.org/10.54963/ti.v9i2.1207
Volume. 9, Issue. 2 ( 2025)
Copyright (c) 2025 Azis Elgondiev, Mustofa Aidid, Talant Omurbekov, Bolotbek Esembaev, Vladimir Poroshchai, Bakit Duysheubaev Oruzbaev, Chyngyz Temirkulov, Saϐiyat Emiraslanova, Yethindra Vityala
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Azis Elgondiev

    Department of Pediatric Surgery, City children’s clinical hospital of emergency medical care, Bishkek 720020, Kyrgyzstan
  • Mustofa Aidid

    Department of Pediatric Surgery, I. K. Akhunbaev Kyrgyz State Medical Academy, Bishkek 720020, Kyrgyzstan
  • Talant Omurbekov

    Department of Pediatric Surgery, I. K. Akhunbaev Kyrgyz State Medical Academy, Bishkek 720020, Kyrgyzstan
  • Bolotbek Esembaev

    Department of Pediatric Urology, National Center Maternal and Child Health, Bishkek 720020, Kyrgyzstan
  • Vladimir Poroshchai

    Department of Pediatric Surgery, I. K. Akhunbaev Kyrgyz State Medical Academy, Bishkek 720020, Kyrgyzstan
  • Bakit Duysheubaev Oruzbaev

    Department of Pediatric Urology, City children’s clinical hospital of emergency medical care, Bishkek 720020, Kyrgyzstan
  • Chyngyz Temirkulov

    Department of Pediatric Urology, City children’s clinical hospital of emergency medical care, Bishkek 720020, Kyrgyzstan
  • Safiyat Emiraslanova

    Department of Pediatric Surgery, I. K. Akhunbaev Kyrgyz State Medical Academy, Bishkek 720020, Kyrgyzstan
  • Yethindra Vityala

    Department of Pathology, International Higher School of Medicine, Bishkek 720054, Kyrgyzstan

Received: 30 April 2025; Revised: 28 May 2025; Accepted: 5 June 2025; Published: 8 June 2025

Cryptorchidism, a common congenital urogenital abnormality affecting 1–5% of full-term male infants, involves the failure of the testicles to descend into the scrotum. This study aimed to evaluate the surgical outcomes in children with cryptorchidism and the effectiveness of rituximab-based immunotherapy for associated paraneoplastic autoimmune encephalitis. This study assessed the surgical outcomes of 1,290 children aged 8 months to 15 years who were treated for cryptorchidism at two facilities in Bishkek, Kyrgyzstan, between 2021-2024. Patients underwent surgery based on testicular location, with 134 treated using the Torek method, 1,055 using the Sokolov method, and 101 using the Petrivalsky/Shoemaker methods. Of the patients who underwent surgery before the age of 3 years, 46.4% had better outcomes. The inguinal region was the most common testicular location (97.1%), with 2.9% of the cases involving abdominal testes. Postoperative ultrasound revealed complications in 62.9% of patients who underwent the Torek method. Three patients with anti-N-methyl-D-aspartate receptor encephalitis associated with germ cell tumors were treated with tumor resection, corticosteroids, plasmapheresis, and rituximab, resulting in neurological recovery in all cases. This study emphasizes the importance of early surgical intervention and multidisciplinary management of cryptorchidism and its associated complications.

Keywords:

Cryptorchidism; Rituximab; Germ Cell Tumor; Anti‑NMDAR Encephalitis; Pediatric Oncology; B Cell Depletion

References

  1. Virtanen, H.E.; Toppari, J. Epidemiology and Pathogenesis of Cryptorchidism. Hum. Reprod. Update 2008, 14, 49–58.
  2. Pakkasjärvi, N.; Taskinen, S. Surgical Treatment of Cryptorchidism: Current Insights and Future Directions. Front. Endocrinol. 2024, 15, 1327957.
  3. Rodprasert, W.; Virtanen, H.E.; Mäkelä, J.A.; et al. Hypogonadism and Cryptorchidism. Front. Endocrinol. 2020, 10, 906.
  4. Thorup, J.; Cortes, D. Long-Term Follow-Up after Treatment of Cryptorchidism. Eur. J. Pediatr. Surg. 2016, 26, 427–431.
  5. Gapany, C.; Frey, P.; Cachat, F.; et al. Management of Cryptorchidism in Children: Guidelines. Swiss Med. Wkly. 2008, 138, 492–498.
  6. Penson, D.; Krishnaswami, S.; Jules, A.; et al. Effectiveness of Hormonal and Surgical Therapies for Cryptorchidism: A Systematic Review. Pediatrics 2013, 131, e1897–e1907.
  7. Rodprasert, W.; Virtanen, H.E.; Toppari, J. Cryptorchidism and Puberty. Front. Endocrinol. 2024, 15, 1347435.
  8. Cortes, D.; Thorup, J.M.; Visfeldt, J. Cryptorchidism: Aspects of Fertility and Neoplasms. A Study Including Data Of 1,335 Consecutive Boys Who Underwent Testicular Biopsy Simultaneously with Surgery for Cryptorchidism. Horm. Res. 2001, 55, 21–27.
  9. Lala, R.; Canavese, F.; Andreo, R.; et al. Testicular Function of Young Men Treated in Childhood for Cryptorchidism. Horm. Res. 2001, 55, 53.
  10. Toppari, J.; Kaleva, M.; Virtanen, H.E. Trends in the Incidence of Cryptorchidism and Hypospadias, and Methodological Limitations of Registry-Based Data. Hum. Reprod. Update 2001, 7, 282–286.
  11. Damgaard, I.N.; Jensen, T.K.; Nordic Cryptorchidism Study Group, et al. Risk Factors for Congenital Cryptorchidism in a Prospective Birth Cohort Study. PLoS One 2008, 3, e3051.
  12. Acerini, C.L.; Miles, H.L.; Dunger, D.B.; et al. The Descriptive Epidemiology of Congenital and Acquired Cryptorchidism in a UK Infant Cohort. Arch. Dis. Child 2009, 94, 868–872.
  13. Barthold, J.S.; González, R. The Epidemiology of Congenital Cryptorchidism, Testicular Ascent and Orchiopexy. J. Urol. 2003, 170, 2396–2401.
  14. Lip, S.Z.; Murchison, L.E.; Cullis, P.S.; et al. A Meta-Analysis of the Risk of Boys with Isolated Cryptorchidism Developing Testicular Cancer in Later Life. Arch. Dis. Child 2013, 98, 20–26.
  15. Sijstermans, K.; Hack, W.W.; Meijer, R.W.; et al. The Frequency of Undescended Testis from Birth to Adulthood: A Review. Int. J. Androl. 2008, 31, 1–11.
  16. Hensel, K.O.; Caspers, T.; Jenke, A.C.; et al. Operative Management of Cryptorchidism: Guidelines and Reality–A 10-Year Observational Analysis of 3587 Cases. BMC Pediatr. 2015, 15, 116.
  17. Gates, R.L.; Shelton, J.; Diefenbach, K.A.; et al. Management of the Undescended Testis in Children: An American Pediatric Surgical Association Outcomes and Evidence Based Practice Committee Systematic Review. J. Pediatr. Surg. 2022, 57, 1293–1308.
  18. Docampo, M.; Hadžiselimović, F. Molecular Pathology of Cryptorchidism-Induced Infertility. Sex Dev. 2015, 9, 269–278.
  19. Samadi, A.A.; Franco, I.; Palmer, L.S. Laparoscopic Orchiopexy: Report of 203 Cases with Review of Diagnosis, Operative Technique, and Lessons Learned. J. Endourol. 2003, 17, 365–368.
  20. El-Anany, F.; El-Moula, M.G.; Moneim, A.A.; et al. Laparoscopy for Impalpable Testis: Classification-Based Management. Surg. Endosc. 2007, 21, 449–454.
  21. Cimsit, C.; Yoldemir, T.; Guclu, M.; et al. Susceptibility-Weighted Magnetic Resonance Imaging for the Evaluation of Deep Infiltrating Endometriosis: Preliminary Results. Acta. Radiol. 2016, 57, 878–885.
  22. Ford, B.; McDonald, A.; Srinivasan, S. Anti-NMDA Receptor Encephalitis: A Case Study and Illness Overview. Drugs Context. 2019, 8, 212589.
  23. Huang, Q.; Xie, Y.; Hu, Z.; et al. Anti-N-methyl-D-aspartate Receptor Encephalitis: A Review of Pathogenic Mechanisms, Treatment, Prognosis. Brain Res. 2020, 1727, 146549.
  24. Samanta, D.; Lui, F. Anti-NMDAR Encephalitis. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2023.
  25. Wang, H. Efficacies of Treatments for Anti-NMDA Receptor Encephalitis. Front. Biosci. 2016, 21, 651–663.
  26. Pham, H.P.; Daniel-Johnson, J.A.; Stotler, B.A.; et al. Therapeutic Plasma Exchange for the Treatment of Anti-NMDA Receptor Encephalitis. J. Clin. Apher. 2011, 26, 320–325.
  27. Tatencloux, S.; Chretien, P.; Rogemond, V.; et al. Intrathecal Treatment of anti-N-Methyl-D-aspartate Receptor Encephalitis in Children. Dev. Med. Child. Neurol. 2015, 57, 95–99.
  28. Shin, Y.W.; Lee, S.T.; Kim, T.J.; et al. Bortezomib Treatment for Severe Refractory anti-NMDA Receptor Encephalitis. Ann. Clin. Transl. Neurol. 2018, 5, 598–605.
  29. Turnbull, M.T.; Siegel, J.L.; Becker, T.L.; et al. Early Bortezomib Therapy for Refractory Anti-NMDA Receptor Encephalitis. Front. Neurol. 2020, 11, 188.
  30. Kondagunta, G.V.; Bacik, J.; Donadio, A.; et al. Combination of Paclitaxel, Ifosfamide, and Cisplatin is an Effective Second-Line Therapy for Patients with Relapsed Testicular Germ Cell Tumors. J. Clin. Oncol. 2005, 23, 6549–6555.
  31. Motzer, R.J.; Cooper, K.; Geller, N.L.; et al. The Role of Ifosfamide Plus Cisplatin-Based Chemotherapy as Salvage Therapy for Patients with Refractory Germ Cell Tumors. Cancer 1990, 66, 2476–2481.
  32. Gershenson, D.M.; Morris, M.; Cangir, A.; et al. Treatment of Malignant Germ Cell Tumors of the Ovary with Bleomycin, Etoposide, and Cisplatin. J. Clin. Oncol. 1990, 8, 715–720.
  33. Broun, E.R.; Nichols, C.R.; Kneebone, P.; et al. Long-Term Outcome of Patients with Relapsed and Refractory Germ Cell Tumors Treated with High-Dose Chemotherapy and Autologous Bone Marrow Rescue. Ann. Intern. Med. 1992, 117, 124–128.
  34. Nichols, C.R.; Tricot, G.; Williams, S.D.; et al. Dose-Intensive Chemotherapy in Refractory Germ Cell Cancer–A Phase I/II Trial of High-Dose Carboplatin and Etoposide with Autologous Bone Marrow Transplantation. J. Clin. Oncol. 1989, 7, 932–939.
  35. McCaffrey, J.A.; Mazumdar, M.; Bajorin, D.F.; et al. Ifosfamide- and Cisplatin-Containing Chemotherapy as First-Line Salvage Therapy in Germ Cell Tumors: Response and Survival. J. Clin. Oncol. 1997, 15, 2559–2563.
  36. Shiraishi, K.; Takihara, H.; Matsuyama, H. Testicular Temperature and the Effects of Orchiopexy in Infants with Cryptorchidism. J. Urol. 2021, 206, 1031–1037.
  37. Cobellis, G.; Noviello, C.; Nino, F.; et al. Spermatogenesis and Cryptorchidism. Front. Endocrinol. 2014, 5, 63.
  38. Lee, P.A.; Coughlin, M.T. Fertility After Bilateral Cryptorchidism. Evaluation by Paternity, Hormone, and Semen Data. Horm. Res. 2001, 55, 28–32.
  39. Thaler, F.S.; Zimmermann, L.; Kammermeier, S.; et al. Rituximab Treatment and Long-term Outcome of Patients with Autoimmune Encephalitis: Real-world Evidence from the GENERATE Registry. Neurol. Neuroimmunol. Neuroinflamm. 2021, 8, e1088.
  40. Ikeguchi, R.; Shibuya, K.; Akiyama, S.; et al. Rituximab Used Successfully in the Treatment of anti-NMDA Receptor Encephalitis. Intern. Med. 2012, 51, 1585–1589.
  41. Armangue, T.; Titulaer, M.J.; Málaga, I.; et al. Pediatric anti-N-methyl-D-aspartate Receptor Encephalitis-Clinical Analysis and Novel Findings in a Series Of 20 Patients. J. Pediatr. 2013, 162, 850–856.e2.
  42. Lee, W.J.; Lee, S.T.; Byun, J.I.; et al. Rituximab Treatment for Autoimmune Limbic Encephalitis in an Institutional Cohort. Neurology 2016, 86, 1683–1691.
  43. Hallowell, S.; Tebedge, E.; Oates, M.; et al. Rituximab for Treatment of Refractory Anti-NMDA Receptor Encephalitis in a Pediatric Patient. J. Pediatr. Pharmacol. Ther. 2017, 22, 118–123.
  44. Reda, M.; Jabbour, R.; Haydar, A.; et al. Case Report: Rapid Recovery After Intrathecal Rituximab Administration in Refractory anti-NMDA Receptor Encephalitis: Report of Two Cases. Front. Immunol. 2024, 15, 1369587.